The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

Diane M. Harper; Pekka Nieminen; Gilbert Donders; Mark H. Einstein; Francisco Garcia; Warner K. Huh; Mark H. Stoler; Katerina Glavini; Gemma Attley; Jean Marc Limacher; Berangere Bastien; Elizabeth Calleja

doi:10.1097/OGX.0000000000000710

The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

Diane M. Harper, Pekka Nieminen, Gilbert Donders, Mark H. Einstein, Francisco Garcia, Warner K. Huh, Mark H. Stoler, Katerina Glavini, Gemma Attley, Jean Marc Limacher, Berangere Bastien, Elizabeth Calleja

Health Promotion Sciences

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.

Original language	English (US)
Pages (from-to)	529-530
Number of pages	2
Journal	Obstetrical and Gynecological Survey
Volume	74
Issue number	9
DOIs	https://doi.org/10.1097/OGX.0000000000000710
State	Published - Sep 1 2019

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1097/OGX.0000000000000710

Cite this

Harper, D. M., Nieminen, P., Donders, G., Einstein, M. H., Garcia, F., Huh, W. K., Stoler, M. H., Glavini, K., Attley, G., Limacher, J. M., Bastien, B., & Calleja, E. (2019). The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up. Obstetrical and Gynecological Survey, 74(9), 529-530. https://doi.org/10.1097/OGX.0000000000000710

The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up. / Harper, Diane M.; Nieminen, Pekka; Donders, Gilbert et al.
In: Obstetrical and Gynecological Survey, Vol. 74, No. 9, 01.09.2019, p. 529-530.

Research output: Contribution to journal › Comment/debate › peer-review

Harper, DM, Nieminen, P, Donders, G, Einstein, MH, Garcia, F, Huh, WK, Stoler, MH, Glavini, K, Attley, G, Limacher, JM, Bastien, B & Calleja, E 2019, 'The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up', Obstetrical and Gynecological Survey, vol. 74, no. 9, pp. 529-530. https://doi.org/10.1097/OGX.0000000000000710

@article{ae4fbc402e1a4a0fa5f8dca3878f81af,

title = "The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up",

abstract = "On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.",

author = "Harper, {Diane M.} and Pekka Nieminen and Gilbert Donders and Einstein, {Mark H.} and Francisco Garcia and Huh, {Warner K.} and Stoler, {Mark H.} and Katerina Glavini and Gemma Attley and Limacher, {Jean Marc} and Berangere Bastien and Elizabeth Calleja",

year = "2019",

month = sep,

day = "1",

doi = "10.1097/OGX.0000000000000710",

language = "English (US)",

volume = "74",

pages = "529--530",

journal = "Obstetrical and Gynecological Survey",

issn = "0029-7828",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "9",

}

TY - JOUR

T1 - The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3

T2 - Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

AU - Harper, Diane M.

AU - Nieminen, Pekka

AU - Donders, Gilbert

AU - Einstein, Mark H.

AU - Garcia, Francisco

AU - Huh, Warner K.

AU - Stoler, Mark H.

AU - Glavini, Katerina

AU - Attley, Gemma

AU - Limacher, Jean Marc

AU - Bastien, Berangere

AU - Calleja, Elizabeth

PY - 2019/9/1

Y1 - 2019/9/1

N2 - On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.

AB - On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.

UR - http://www.scopus.com/inward/record.url?scp=85077575722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077575722&partnerID=8YFLogxK

U2 - 10.1097/OGX.0000000000000710

DO - 10.1097/OGX.0000000000000710

M3 - Comment/debate

AN - SCOPUS:85077575722

SN - 0029-7828

VL - 74

SP - 529

EP - 530

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

IS - 9

ER -

The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this